Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (RBV).

Massimo, A., Teti, E., Antinori, A., Milazzoi, L., Sollima, S., Rizzardini, G., et al. (2017). Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. CLINICAL INFECTIOUS DISEASES, 64(5), 680-683 [10.1093/cid/ciw846].

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program

Teti E;
2017-01-01

Abstract

Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) +/- ribavirin (RBV).
2017
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/17 - MALATTIE INFETTIVE
English
HIV/HCV coinfection
DAA
IFN-free
antiviral therapy
anti-HCV therapy
Massimo, A., Teti, E., Antinori, A., Milazzoi, L., Sollima, S., Rizzardini, G., et al. (2017). Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. CLINICAL INFECTIOUS DISEASES, 64(5), 680-683 [10.1093/cid/ciw846].
Massimo, A; Teti, E; Antinori, A; Milazzoi, L; Sollima, S; Rizzardini, G; Di Biagio, A; Saracino, A; Bruno, R; Borghi, V; De Luca, A; Cattelan, A; Has...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/283713
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact